Prime Highlights
- Novo Nordisk plans to seek Chinese regulatory approval for its Wegovy weight-loss pill, targeting one of the world’s largest pharmaceutical markets.
- The move intensifies competition with Eli Lilly as both companies race to expand the market for oral weight-loss treatments.
Key Facts
- Wegovy pill contains semaglutide, the same active ingredient used in Novo Nordisk’s blockbuster injectable drugs Wegovy and Ozempic.
- GLP-1 drug sales on Alibaba and JD.com reached approximately 4 billion yuan ($207 million) in the first quarter, highlighting strong demand in China.
Background
Novo Nordisk is preparing to seek regulatory approval for its weight-loss pill in China, with Chief Executive Mike Doustdar saying the filing will happen very soon. The move puts the Danish drugmaker in direct competition with American rival Eli Lilly in one of the world’s biggest pharmaceutical markets.
The push into China comes as both companies race to expand oral weight-loss medicines. Pills have become a growing priority because many patients are reluctant to use injections, and both Novo and Eli Lilly see strong demand for a tablet-based alternative.
Eli Lilly moved first. The company submitted a marketing application for its once-daily oral drug, orforglipron, to China’s drug regulator at the end of 2025. Novo Nordisk is now looking to close that gap.
Novo’s Wegovy pill carries semaglutide as its active ingredient, the same compound found in its widely used injectable Wegovy and Ozempic. The pill has already received approval in the United States and the United Kingdom, giving the company a proven product to bring into the Chinese market.
The appetite for weight-loss drugs in China is already visible in sales numbers. GLP-1 medicines sold through Alibaba and JD.com, two of the country’s largest e-commerce platforms, brought in around 1.4 billion yuan, roughly 207 million US dollars, in the first quarter alone, according to data from investment bank Jefferies.
GLP-1 drugs have reshaped the global pharmaceutical industry over the past few years, turning weight-loss treatment into one of the most competitive spaces in medicine.
Both Novo Nordisk and Eli Lilly are betting that an oral option will bring in a new wave of patients who have stayed away from injectable treatments.
China, with its large population and rising rates of obesity, remains one of the most important markets either company can enter.